Cargando…
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927326/ https://www.ncbi.nlm.nih.gov/pubmed/31407010 http://dx.doi.org/10.1093/annonc/mdz215 |
_version_ | 1783482285915373568 |
---|---|
author | Hortobagyi, G N Stemmer, S M Burris, H A Yap, Y S Sonke, G S Paluch-Shimon, S Campone, M Petrakova, K Blackwell, K L Winer, E P Janni, W Verma, S Conte, P Arteaga, C L Cameron, D A Mondal, S Su, F Miller, M Elmeliegy, M Germa, C O’Shaughnessy, J |
author_facet | Hortobagyi, G N Stemmer, S M Burris, H A Yap, Y S Sonke, G S Paluch-Shimon, S Campone, M Petrakova, K Blackwell, K L Winer, E P Janni, W Verma, S Conte, P Arteaga, C L Cameron, D A Mondal, S Su, F Miller, M Elmeliegy, M Germa, C O’Shaughnessy, J |
author_sort | Hortobagyi, G N |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-6927326 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-69273262019-12-27 Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer Hortobagyi, G N Stemmer, S M Burris, H A Yap, Y S Sonke, G S Paluch-Shimon, S Campone, M Petrakova, K Blackwell, K L Winer, E P Janni, W Verma, S Conte, P Arteaga, C L Cameron, D A Mondal, S Su, F Miller, M Elmeliegy, M Germa, C O’Shaughnessy, J Ann Oncol Corrigenda Oxford University Press 2019-11 2019-08-13 /pmc/articles/PMC6927326/ /pubmed/31407010 http://dx.doi.org/10.1093/annonc/mdz215 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Corrigenda Hortobagyi, G N Stemmer, S M Burris, H A Yap, Y S Sonke, G S Paluch-Shimon, S Campone, M Petrakova, K Blackwell, K L Winer, E P Janni, W Verma, S Conte, P Arteaga, C L Cameron, D A Mondal, S Su, F Miller, M Elmeliegy, M Germa, C O’Shaughnessy, J Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer |
title | Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer |
title_full | Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer |
title_fullStr | Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer |
title_full_unstemmed | Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer |
title_short | Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer |
title_sort | updated results from monaleesa-2, a phase iii trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, her2-negative advanced breast cancer |
topic | Corrigenda |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927326/ https://www.ncbi.nlm.nih.gov/pubmed/31407010 http://dx.doi.org/10.1093/annonc/mdz215 |
work_keys_str_mv | AT hortobagyign updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer AT stemmersm updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer AT burrisha updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer AT yapys updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer AT sonkegs updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer AT paluchshimons updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer AT camponem updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer AT petrakovak updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer AT blackwellkl updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer AT winerep updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer AT janniw updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer AT vermas updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer AT contep updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer AT arteagacl updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer AT cameronda updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer AT mondals updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer AT suf updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer AT millerm updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer AT elmeliegym updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer AT germac updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer AT oshaughnessyj updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer |